The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and/or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

Use of 5-methyltetrahydrofolate in preparing a medicine or health-care food for preventing neonatal congenital heart disease in peri-pregnancy and/or pregnant women has an effect of preventing congenital heart disease. The prophylactic dosage of the 5-methyltetrahydrofolate can be greater than 1 mg. Compared with synthetic folic acid, high-dose use has no teratogenic effect. Thus the 5-methyltetrahydrofolate can prevent birth defects in a high dose and can be used for preventing neonatal congenital heart disease.

Use of 5-methyltetrahydrofolate in preparing a medicine or health-care food for preventing neonatal congenital heart disease in peri-pregnancy and/or pregnant women has an effect of preventing congenital heart disease. The prophylactic dosage of the 5-methyltetrahydrofolate can be greater than 1 mg. Compared with synthetic folic acid, high-dose use has no teratogenic effect. Thus the 5-methyltetrahydrofolate can prevent birth defects in a high dose and can be used for preventing neonatal congenital heart disease.

The present invention relates to Human Immunodeficiency Virus (HIV) treatment. In particular, the invention relates to a pharmaceutical composition comprising cabotegravir or a pharmaceutically acceptable salt thereof, polyethylene glycol and poloxamer useful as a long acting HIV treatment.

Provided is a liquid preparation containing an anti-IL-17 antibody at a concentration of 20 mg/mL to 200 mg/mL, a citrate buffer at a concentration of 10 mM to 50 mM, a sucrose at a concentration of 20 mg/mL to 120 mg/mL or arginine at a concentration of 50 mM to 250 mM, and polysorbate 80 at a concentration of 0.1 mg/mL to 5 mg/mL. In addition, the liquid preparation has a pH of 6.0±0.5, wherein the anti-IL-17 antibody is an anti-IL-17A/F monoclonal antibody. The liquid preparation can be a stable subcutaneous injection preparation, and can be used to treat IL-17A and/or IL-17F related diseases, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, osteoarthritis or inflammatory bowel disease.

The present invention relates to a self-sealable injection needle for inhibiting formation of fistula on an eyeball, and a method for manufacturing same. More specifically, the self-sealable injection needle for inhibiting formation of fistula on an eyeball, which is coated with hyaluronic acid on the surface thereof, can immediately close a hole that is inevitably formed when the injection needle is pulled out of an eyeball during the application of an ocular injection to prevent leakage of aqueous humor and to prevent backflow of drug out of the eyeball and can block bacterial penetration to prevent infection in the eyeball.

Disclosed herein are compositions and methods for ovulation induction in females in need thereof. Current methods for inducing ovulation have unpleasant side effects and are expensive. The disclosed compositions and methods are safe, efficacious, and inexpensive. An exemplary method of inducing ovulation includes steps of monitoring ovarian follicle development and size during the follicular phase of the menstrual cycle; and administering to the subject a pharmaceutical composition including progesterone or ioidentical progesterone in an amount effective to increase the plasma concentration of progesterone to between about 0.1 ng/ml to about 1 ng/ml when the follicle reaches a size of at least 15 mm.

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Further disclosed herein is an ophthalmic including a low concentration of an ophthalmic agent and various ratios of water to deuterated water.